Products
Tigecycline is commercially available as a dry substance for the preparation of an infusion solution (Tygacil). It has been approved in many countries since 2007.
Effects
Tigecycline (ATC J01AA12) has bacteriostatic properties. It inhibits translation in bacterial protein synthesis by binding to the 30S subunit of ribosomes and preventing the attachment of aminoacyl-tRNA molecules to the ribosomal acceptor site (A-site).
Indications
For treatment of complicated bacterial infectious diseases with susceptible pathogens.
